New pill tested to help control stubborn diabetes

NCT ID NCT07502495

Recruiting now Disease control Sponsor: Biomea Fusion Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new oral drug called icovamenib can help lower blood sugar levels in adults with type 2 diabetes who are not reaching their targets with their current medications. About 60 participants will take either icovamenib or a placebo (a pill with no medicine) daily for 12 weeks, while continuing their standard diabetes care. The main goal is to see if adding icovamenib leads to better blood sugar control compared to current treatments alone.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alliance Clinical Las Vegas
RECRUITING

Las Vegas, Nevada, 89109, United States
Ark Clinical Research
RECRUITING

Long Beach, California, 90815, United States
Epic Clinical Research
RECRUITING

Lewisville, Texas, 75057, United States
Hope Clinical Research
RECRUITING

Canoga Park, California, 91303, United States
Panax Clinical Research
RECRUITING

Miami Lakes, Florida, 33014, United States
Southwest General Healthcare Center
RECRUITING

Fort Myers, Florida, 33907, United States
Synergy Groups Medical
RECRUITING

Houston, Texas, 77061, United States

Conditions

Explore the condition pages connected to this study.

TYPE 2 DIABETES